Aethlon Shares Jump Before '60 Minutes' Report On CTE, Vets
Aethlon Medical (NASDAQ: AEMD) reportedly plays a part in a “60 Minutes” segment on CTE in combat veterans that’s airing Sunday.
The story says combat veterans exposed to bomb blasts are being diagnosed with CTE much like NFL players with a history of concussions.
Aethlon shares traded up as much as 35 percent in Friday trading. The stock closed Friday at $1.56.
Seeking Alpha reports that Aethlon is the majority owner of Exosome Sciences, which has found a biomarker, TauSome, that could be used to detect CTE in sufferers who are still living.
CTE, which a study found in 110 of the 111 brains of former NFL players, is diagnosed in 65 percent of combat veterans who were studied, according to CBS Corporation (NYSE: CBS).
Related Link:
Posted-In: 60 minutes Aethlon Medical CTE Exosome Sciences TauSomeBiotech Media General Best of Benzinga
© 2018 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
